# Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

> **NCT02069093** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 92 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Dexamethasone based mouthwash
- **DRUG:** Everolimus
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT02069093
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2017-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069093, "Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02069093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*